Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00878904 · ClinicalTrials.gov registry record · Phase 1
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00878904 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 40 participants.
The verdict
NCT00878904, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving panobinostat together with epirubicin may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when given together with epirubicin in treating patients with metastatic malignant solid tumors.
Interventions
- GENETIC gene expression analysis
- GENETIC protein expression analysis
- DRUG panobinostat
- DRUG epirubicin hydrochloride
- GENETIC western blotting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-09-13 |
| Est. Completion | 2016-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00878904
The ClinicalTrials.gov registry entry for NCT00878904 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00878904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00878904 about?
NCT00878904 is a clinical study titled "Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors". RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving panobinos...
What is the current status of trial NCT00878904?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2009-09-13. Estimated completion is 2016-10-10.
What interventions are being tested in trial NCT00878904?
The interventions under investigation include: gene expression analysis (GENETIC), protein expression analysis (GENETIC), panobinostat (DRUG), epirubicin hydrochloride (DRUG), western blotting (GENETIC).
Who is sponsoring clinical trial NCT00878904?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.